Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 87892 | 1.96 |
09:34 ET | 54549 | 1.9775 |
09:36 ET | 4514 | 1.98 |
09:38 ET | 78111 | 2.0001 |
09:39 ET | 30488 | 1.9811 |
09:41 ET | 33580 | 1.94 |
09:43 ET | 62989 | 1.94 |
09:45 ET | 48306 | 1.9207 |
09:48 ET | 21049 | 1.9799 |
09:50 ET | 14680 | 1.9593 |
09:52 ET | 45820 | 1.955 |
09:54 ET | 117661 | 1.985 |
09:56 ET | 24384 | 1.965 |
09:57 ET | 8139 | 1.9607 |
09:59 ET | 19624 | 1.975 |
10:01 ET | 14894 | 1.99 |
10:03 ET | 20101 | 1.985 |
10:06 ET | 55301 | 2 |
10:08 ET | 19628 | 2.005 |
10:10 ET | 15126 | 2 |
10:12 ET | 38011 | 1.9901 |
10:14 ET | 5220 | 1.99 |
10:15 ET | 2488 | 1.99 |
10:17 ET | 34363 | 2 |
10:19 ET | 40191 | 1.99 |
10:21 ET | 2652 | 1.9902 |
10:24 ET | 12170 | 1.99 |
10:26 ET | 29540 | 1.9899 |
10:28 ET | 6014 | 1.985 |
10:30 ET | 16887 | 1.99 |
10:32 ET | 13497 | 1.98 |
10:33 ET | 3989 | 1.98 |
10:35 ET | 54044 | 1.97 |
10:37 ET | 42462 | 1.985 |
10:39 ET | 50414 | 1.98 |
10:42 ET | 10750 | 1.98 |
10:44 ET | 3982 | 1.98 |
10:46 ET | 32311 | 1.975 |
10:48 ET | 91984 | 1.97 |
10:50 ET | 128704 | 1.965 |
10:51 ET | 7944 | 1.96 |
10:53 ET | 55258 | 1.975 |
10:55 ET | 10126 | 1.97 |
10:57 ET | 29394 | 1.9601 |
11:00 ET | 2643 | 1.96 |
11:02 ET | 1400 | 1.96 |
11:04 ET | 6322 | 1.965 |
11:06 ET | 4200 | 1.97 |
11:08 ET | 67006 | 1.97 |
11:09 ET | 5404 | 1.98 |
11:11 ET | 2101 | 1.97 |
11:13 ET | 4495 | 1.975 |
11:15 ET | 8304 | 1.975 |
11:18 ET | 8550 | 1.975 |
11:20 ET | 4379 | 1.97 |
11:22 ET | 6714 | 1.975 |
11:24 ET | 253841 | 2 |
11:26 ET | 79063 | 2 |
11:27 ET | 2801 | 1.995 |
11:29 ET | 84224 | 1.99 |
11:31 ET | 84534 | 1.975 |
11:33 ET | 19090 | 1.97 |
11:36 ET | 7402 | 1.97 |
11:38 ET | 4341 | 1.98 |
11:40 ET | 25497 | 1.98 |
11:42 ET | 2933 | 1.985 |
11:44 ET | 29982 | 1.985 |
11:45 ET | 6290 | 1.99 |
11:47 ET | 3094 | 1.985 |
11:49 ET | 21978 | 2.005 |
11:51 ET | 14805 | 2 |
11:54 ET | 4578 | 1.98 |
11:56 ET | 6396 | 1.9834 |
11:58 ET | 35464 | 1.995 |
12:00 ET | 154206 | 2 |
12:02 ET | 83063 | 1.98 |
12:03 ET | 6482 | 1.99 |
12:05 ET | 2721 | 1.98 |
12:07 ET | 5200 | 1.98 |
12:09 ET | 1800 | 1.9899 |
12:12 ET | 1924 | 1.98 |
12:14 ET | 1300 | 1.98 |
12:16 ET | 1900 | 1.98 |
12:18 ET | 700 | 1.98 |
12:20 ET | 2193 | 1.98 |
12:21 ET | 1233 | 1.985 |
12:23 ET | 21824 | 1.995 |
12:25 ET | 6784 | 1.995 |
12:27 ET | 4225 | 1.99 |
12:30 ET | 15593 | 1.985 |
12:32 ET | 1560 | 1.985 |
12:34 ET | 652 | 1.985 |
12:36 ET | 3397 | 1.98 |
12:38 ET | 900 | 1.985 |
12:39 ET | 10665 | 1.9825 |
12:41 ET | 23177 | 1.99 |
12:43 ET | 14140 | 1.995 |
12:45 ET | 5045 | 1.9907 |
12:48 ET | 533 | 1.995 |
12:50 ET | 2881 | 1.99 |
12:52 ET | 1250 | 1.99 |
12:54 ET | 4639 | 1.995 |
12:56 ET | 99646 | 1.97 |
12:57 ET | 3350 | 1.97 |
12:59 ET | 744 | 1.97 |
01:01 ET | 46531 | 1.97 |
01:03 ET | 46657 | 1.985 |
01:06 ET | 23222 | 1.985 |
01:08 ET | 5539 | 1.98 |
01:10 ET | 5521 | 1.98 |
01:12 ET | 700 | 1.98 |
01:14 ET | 1434 | 1.985 |
01:15 ET | 1222 | 1.985 |
01:17 ET | 3300 | 1.985 |
01:19 ET | 50896 | 1.995 |
01:21 ET | 10837 | 1.995 |
01:24 ET | 2500 | 1.99 |
01:26 ET | 5282 | 1.995 |
01:28 ET | 19596 | 1.995 |
01:30 ET | 1100 | 1.995 |
01:32 ET | 3700 | 1.995 |
01:33 ET | 52955 | 1.99 |
01:35 ET | 173856 | 1.995 |
01:37 ET | 7295 | 1.995 |
01:39 ET | 9366 | 1.98 |
01:42 ET | 1709 | 1.985 |
01:44 ET | 19523 | 1.975 |
01:46 ET | 800 | 1.975 |
01:48 ET | 5845 | 1.97 |
01:50 ET | 5103 | 1.97 |
01:51 ET | 73991 | 1.95 |
01:53 ET | 64294 | 1.95 |
01:55 ET | 7498 | 1.95 |
01:57 ET | 2318 | 1.95 |
02:00 ET | 4100 | 1.955 |
02:02 ET | 4120 | 1.95 |
02:04 ET | 3207 | 1.95 |
02:06 ET | 1738 | 1.95 |
02:08 ET | 24352 | 1.94 |
02:09 ET | 13807 | 1.95 |
02:11 ET | 12160 | 1.95 |
02:13 ET | 13849 | 1.94 |
02:15 ET | 4546 | 1.94 |
02:18 ET | 13839 | 1.94 |
02:20 ET | 4784 | 1.945 |
02:22 ET | 5000 | 1.94 |
02:24 ET | 11250 | 1.94 |
02:26 ET | 6000 | 1.94 |
02:27 ET | 5577 | 1.9472 |
02:29 ET | 58564 | 1.9556 |
02:31 ET | 5426 | 1.955 |
02:33 ET | 109649 | 1.94 |
02:36 ET | 4865 | 1.94 |
02:38 ET | 6428 | 1.94 |
02:40 ET | 3779 | 1.94 |
02:42 ET | 6234 | 1.93 |
02:44 ET | 10188 | 1.93 |
02:45 ET | 4756 | 1.93 |
02:47 ET | 9801 | 1.93 |
02:49 ET | 9656 | 1.93 |
02:51 ET | 7395 | 1.935 |
02:54 ET | 23290 | 1.9299 |
02:56 ET | 2906 | 1.92 |
02:58 ET | 3131 | 1.9201 |
03:00 ET | 6296 | 1.92 |
03:02 ET | 12666 | 1.92 |
03:03 ET | 67263 | 1.905 |
03:05 ET | 70164 | 1.91 |
03:07 ET | 10656 | 1.91 |
03:09 ET | 64751 | 1.89 |
03:12 ET | 60095 | 1.905 |
03:14 ET | 13789 | 1.905 |
03:16 ET | 42012 | 1.9015 |
03:18 ET | 16806 | 1.9 |
03:20 ET | 26599 | 1.9 |
03:21 ET | 22613 | 1.895 |
03:23 ET | 87023 | 1.89 |
03:25 ET | 25707 | 1.9 |
03:27 ET | 44928 | 1.89 |
03:30 ET | 6563 | 1.89 |
03:32 ET | 124052 | 1.9091 |
03:34 ET | 18043 | 1.915 |
03:36 ET | 199229 | 1.925 |
03:38 ET | 26945 | 1.925 |
03:39 ET | 40406 | 1.935 |
03:41 ET | 21919 | 1.92 |
03:43 ET | 28260 | 1.915 |
03:45 ET | 7463 | 1.91 |
03:48 ET | 54460 | 1.905 |
03:50 ET | 36405 | 1.8966 |
03:52 ET | 104152 | 1.89 |
03:54 ET | 60089 | 1.89 |
03:56 ET | 65144 | 1.895 |
03:57 ET | 59862 | 1.895 |
03:59 ET | 174741 | 1.89 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 147.3M | 9.6x | --- |
Spero Therapeutics Inc | 88.9M | 4.1x | --- |
2Seventy Bio Inc | 230.8M | -1.0x | --- |
Rigel Pharmaceuticals Inc | 172.3M | -8.7x | --- |
Seres Therapeutics Inc | 145.7M | -1.6x | --- |
Alimera Sciences Inc | 182.3M | -1.6x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $147.3M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.16 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 9.6x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | 7.9x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.